Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

更换36.jpg

Litchlab | Your CDMO Partner for Microsphere & Nanoparticle Drug Delivery Systems

Litchlab is a specialized CDMO dedicated to the development, optimization, and GMP-compliant manufacturing of advanced microsphere and nanoparticle-based drug delivery systems. Our integrated services help pharmaceutical partners overcome formulation challenge...

Litchlab | Your Trusted Partner for Liposome-Based Drug Delivery Solutions

Litchlab is a specialized CDMO dedicated to the research, development, and production of liposome-based drug delivery systems. We offer comprehensive services that cover the entire drug development cycle — from early-stage formulation design to clinical batch ...

Litchlab: Empowering the Next Wave of Precision Therapeutics with Full-Spectrum ADC & RDC CDMO Solutions

As precision medicine reshapes the treatment paradigm for oncology and beyond, Antibody-Drug Conjugates (ADCs) and Radiopharmaceutical Drug Conjugates (RDCs) have emerged as powerful therapeutic modalities that unite specific targeting with potent cytotoxic or...

修改后.jpg

Litchlab: Redefining Liposomal Drug Delivery with Next-Generation CDMO Solutions

In the rapidly evolving therapeutic landscape, liposomal drug delivery has emerged as a vital platform for addressing complex diseases—including cancer, infectious diseases, genetic disorders, and immunotherapies. Litchlab, an innovation-driven Contract Develo...

Litchlab Unveils Comprehensive CDMO Platform for Liposomal & Nanocarrier Therapeutics: From Bench to GMP

As precision medicine continues to evolve, the demand for advanced lipid-based drug delivery systems has surged—particularly for therapies involving siRNA, mRNA, antibody-drug conjugates, radiopharmaceuticals, and targeted chemotherapeutics. In response to thi...

Litchlab Emerges as a Leading Innovator in Intelligent Liposomal Drug Delivery

As the global biopharma industry accelerates toward precision medicine, lipid-based nanocarriers have become critical enablers of targeted and controllable drug delivery. Among the next-generation biotech companies reshaping this space, Litchlab is gaining pro...

上一页 1 2 3 4 5 下一页